Peginterferon Lambda (Lambda)
Hepatitis Delta Virus Infection
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Peginterferon Lambda (Lambda) for Hepatitis Delta Virus Infection
ClinicalTrials.gov (NCT03600714) Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
WHAT IS THE NEXT CATALYST EVENT?
Phase 2 LIFT (combo with lonafarnib) end-of-study data expected at AASLD 2020 Agreement with FDA and EMA on single, Phase 3 Lambda monotherapy study design
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
11-16-2020 Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience™ 2020
11-12-2020 Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019
MECHANISM OF ACTION
Lonafarnib is a well-characterized, late-stage, oral inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation, a vital process in the life cycle of HDV. Blocking prenylation of the large delta hepatitis antigen (LDHAg) reduces HDV replication.
Updated by JM
#EIGR, EIGER, HDV, Hepatitis Delta Virus Infection, Peginterferon Lambda (Lambda)
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post